辛伐他汀联合二甲双胍协同抑制子宫内膜癌细胞生长
研究在RL95-2、HEC1B和Ishikawa三种子宫内膜癌细胞系中测试辛伐他汀(SIM)与二甲双胍(MET)联合的体外抗增殖效应。结果显示MET+SIM协同抑制所有三种细胞系生长,诱导凋亡,且该效应可被Bim siRNA转染逆转;机制涉及上调磷酸化AMPK和下调磷酸化S6,提示mTOR通路抑制。作者认为这一临床前证据提示该联合方案可能值得进一步临床研究。
要点
- MET+SIM在三种子宫内膜癌细胞系中协同抑制细胞生长。
- 联合处理诱导凋亡,Bim siRNA转染可逆转该效应。
- 联合处理上调磷酸化AMPK并下调磷酸化S6,提示mTOR抑制。
核心结论
- MET+SIM协同抑制子宫内膜癌细胞活力,可能由凋亡和mTOR通路抑制介导。
- 作者认为这些结果提供临床前证据,提示该联合方案可能值得进一步临床研究用于子宫内膜癌治疗。
研究设计与样本
- 体外研究,使用RL95-2、HEC1B和Ishikawa三种子宫内膜癌细胞系,分别以MET和/或SIM处理。
- 采用MTS细胞增殖实验检测生长抑制,采用caspase-3、Annexin V和TUNEL实验及western blot检测凋亡标志物(BAX、Bcl-2、Bim)。
- 使用Bim siRNA沉默Bim以验证凋亡通路,并以磷酸化AMPK和磷酸化S6抗体通过western blot研究mTOR通路。
主要发现
- MET+SIM在全部三种细胞系中协同抑制生长。
- 联合处理经TUNEL、Annexin V和caspase-3实验检测诱导凋亡。
- 在MET+SIM处理的RL95-2细胞中,Bim siRNA转染较对照siRNA转染细胞恢复了MTS实验中的细胞活力并降低了caspase-3活性。
- 联合处理上调磷酸化AMPK并下调下游磷酸化S6。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent data show that simvastatin (SIM) and metformin (MET) have anti-proliferative effects in endometrial cancer cells. The combination (MET+SIM) inhibits tumor growth and metastasis in prostate cancer cells which possess similar molecular alterations to many early endometrial cancers. We tested the hypothesis that the anti-proliferative effects of MET+SIM in endometrial cancer cells would be greater than the effects of each agent alone. METHODS: RL95-2, HEC1B, and Ishikawa endometrial cancer cell lines were treated with MET and/or SIM. Growth inhibition was measured by MTS cell proliferation assays. Apoptosis was evaluated by caspase-3, Annexin V, and TUNEL assays and by apoptosis markers (BAX, Bcl-2, Bim) using western blot. Bim was silenced using Bim siRNA to confirm this apoptotic pathway. Treatment effects on the mTOR pathway were investigated by western blot using antibodies to phosphorylated (phospho)-AMPK and phospho-S6. RESULTS: MET+SIM synergistically inhibited growth in all three cell lines. The combination induced apoptosis as measured by TUNEL, Annexin V, and caspase-3 assays. Bim siRNA transfection abrogated this effect-silencing Bim in MET+SIM-treated RL95-2 cells rescued cell viability in MTS assays and reduced caspase-3 activity compared with control siRNA-transfected cells. Combination treatment upregulated phosphorylated AMPK and downregulated downstream phosphorylated S6, suggesting mTOR inhibition as a mechanism for these anti-proliferative effects. CONCLUSIONS: MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment.
引用
- Kim JS, Turbov J, Rosales R, et al. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019. PMID: 31178149. doi:10.1016/j.ygyno.2019.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。